tetano
Editor, Senior Moderator
Nat Commun
. 2023 Aug 24;14(1):5171.
doi: 10.1038/s41467-023-40960-0. SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Andrew P Hederman[SUP] 1 [/SUP], Harini Natarajan[SUP] 2 [/SUP], Leo Heyndrickx[SUP] 3 [/SUP], Kevin K Ariën[SUP] 3 [/SUP], Joshua A Wiener[SUP] 1 [/SUP], Peter F Wright[SUP] 4 [/SUP], Evan M Bloch[SUP] 5 [/SUP], Aaron A R Tobian[SUP] 5 [/SUP], Andrew D Redd[SUP] 6 7 [/SUP], Joel N Blankson[SUP] 6 [/SUP], Amihai Rottenstreich[SUP] 8 [/SUP], Gila Zarbiv[SUP] 9 [/SUP], Dana Wolf[SUP] 9 [/SUP], Tessa Goetghebuer[SUP] 10 11 [/SUP], Arnaud Marchant[SUP] 10 [/SUP], Margaret E Ackerman[SUP] 12 13 [/SUP]
Affiliations
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
. 2023 Aug 24;14(1):5171.
doi: 10.1038/s41467-023-40960-0. SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Andrew P Hederman[SUP] 1 [/SUP], Harini Natarajan[SUP] 2 [/SUP], Leo Heyndrickx[SUP] 3 [/SUP], Kevin K Ariën[SUP] 3 [/SUP], Joshua A Wiener[SUP] 1 [/SUP], Peter F Wright[SUP] 4 [/SUP], Evan M Bloch[SUP] 5 [/SUP], Aaron A R Tobian[SUP] 5 [/SUP], Andrew D Redd[SUP] 6 7 [/SUP], Joel N Blankson[SUP] 6 [/SUP], Amihai Rottenstreich[SUP] 8 [/SUP], Gila Zarbiv[SUP] 9 [/SUP], Dana Wolf[SUP] 9 [/SUP], Tessa Goetghebuer[SUP] 10 11 [/SUP], Arnaud Marchant[SUP] 10 [/SUP], Margaret E Ackerman[SUP] 12 13 [/SUP]
Affiliations
- PMID: 37620337
- DOI: 10.1038/s41467-023-40960-0
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.